February 23, 2011
Onglyza labeling updated to include new clinical trial data
Data from a separate 52-week, randomized, double-blind, active-controlled study of 858 adult patients with type 2 diabetes and inadequate glycemic control comparing Onglyza + metformin to glipizide + metformin showed that Onglyza + metformin provided similar HbA1c reductions from baseline. This conclusion may be limited to patients with baseline HbA1c comparable to those in the trial. Onglyza + metformin also resulted in significantly less confirmed hypoglycemia, as well as weight loss compared to weight gain, versus titrated glipizide + metformin.
For more information call (800) 321-1335 or visit www.onglyza.com.